Boostrix Polio

Boostrix Polio

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Per 0.5 mL dose Diphtheria toxoid not <2 IU, tetanus toxoid not <20 IU, 3 Bordetella pertussis antigens (pertussis toxoid 8 mcg, filamentous haemagglutinin 8 mcg, pertactin 2.5 mcg), inactivated poliovirus [type 1 (Mahoney strain) 40 D-antigen u, type 2 (MEF-1 strain) 8 D-antigen u, type 3 (Saukett strain) 32 D-antigen u]
Indications/Uses
Booster vaccination against DPT & poliomyelitis for individuals ≥3 yr. Passive protection against pertussis in early infancy following maternal immunisation during pregnancy.
Dosage/Direction for Use
Contraindications
Hypersensitivity or patients having signs of hypersensitivity after previous administration of DPT or poliomyelitis vaccines. Encephalopathy of unknown aetiology occurring w/in 7 days following previous vaccination w/ pertussis-containing vaccine. Neurological complications following earlier immunisation against diphtheria &/or tetanus (for convulsions or hypotonic-hyporesponsive episodes).
Special Precautions
Postpone vaccination in patients suffering from acute severe febrile illness. Not to be administered intravascularly. Patients w/ thrombocytopenia or bleeding disorder. Immunosuppressed patients (eg, on immunosuppressive therapy). History of febrile convulsions; family history of convulsions, sudden infant death syndrome & adverse event following DPT vaccination. Syncope. Perform review of medical history & clinical exam before vaccination. Carefully consider giving subsequent doses of pertussis-containing vaccines for temp ≥40°C (rectal) w/in 48 hr of vaccination, not due to another identifiable cause; collapse or shock-like state (hypotonic-hyporesponsive episode) w/in 48 hr of vaccination; persistent, inconsolable crying lasting ≥3 hr, occurring w/in 48 hr of vaccination; convulsions w/ or w/o fever, occurring w/in 3 days of vaccination. Defer pertussis immunisation in childn w/ progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Lactation. Not for primary immunisation of childn <3 yr.
Adverse Reactions
Somnolence, headache; inj site reactions (including pain, redness, swelling), fatigue. Anorexia; irritability; GI disorders; fever ≥37.5°C (including fever >39°C), inj site reactions (eg, haemorrhage, haematoma).
Drug Interactions
Concomitant use w/ immunosuppressants.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07CA02 - diphtheria-pertussis-poliomyelitis-tetanus ; Belongs to the class of combined bacterial and viral vaccines.
Presentation/Packing
Form
Boostrix Polio susp for inj 0.5 mL
Packing/Price
0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in